Zydus Lifesciences has received final approval from the United States Food and Drug Administration USFDA to market Famotidine Injection USP 40 mg4 mL 10 mgmL and 200 mg20 mL 10 mgmL multiple-dose vials USRLD Pepcid injection Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed This medication is also used to treat certain stomach and throat esophagus problems such as erosive esophagitis gastroesophageal reflux disease-GERD and Zollinger-Ellison syndrome Famotidine Injection had annual sales of USD 19 mn in the United States according to IQVIA data IQVIA MAT Sep 2022 The drug will be manufactured at the groups injectable manufacturing facility at Jarod near Vadodara India
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
